Table 1.
Clinical details of the Rheumatoid Arthritis patients and healthy donors.
| RA patients | Healthy donors | p-value | |
|---|---|---|---|
| 1st cohort (PRECISESADS) | n = 140 | n = 145 | |
| Clinical parameters | |||
| Women/men, n/n | 103/37 | 112/34 | 0.539 |
| Age, y | 56.66 ± 12.68 | 46.29 ± 13.25 | < 0.001 |
| Evolution time, y | 13.42 ± 10.20 | … | |
| RF positive, (%) | 72/140 (51.40%) | … | |
| ACPAs, (%) | 93/140 (66.40%) | … | |
| Smoker, (%) | 33/140 (23.57%) | 10/140 (6.89%) | 0.000 |
| Laboratory parameters | |||
| CRP, mg/L | 5.96 ± 17.9 | 1.49 ± 1.9 | 0.004 |
| Treatments | |||
| Corticosteroids, (%) | 60/140 (42.90%) | … | |
| Anti-malarials, (%) | 15/140 (10.70%) | … | |
| Immunosuppressants, (%) | 108/140 (77.10%) | … | |
| Biologics, (%) | 74/140 (52.90%) | … | |
| 2nd cohort | n = 50 | n = 33 | |
| Clinical parameters | |||
| Women/men, n/n | 30/20 | 24/9 | 0.263 |
| Age, y | 51.55 ± 11.53 | 46.70 ± 9.03 | 0.051 |
| Evolution time, y | 5.91 ± 6.1 | … | |
| Pathological CMIT | 11/28 (39.28%) | 0/7 (0.00%) | 0.032 |
| RF positive, (%) | 28/46 (60.86%) | … | |
| ACPAs, (%) | 38/45 (84.44%) | … | |
| DAS28 | 3.18 ± 1.19 | … | |
| Hypertension, (%) | 9/43 (20.93%) | 1/33 (3.00%) | 0.090 |
| Smoker, (%) | 11/43 (25.58%) | 5/33 (15.15%) | 0.508 |
| Laboratory parameters | |||
| CRP, mg/L | 7.41 ± 11.02 | 1.27 ± 1.88 | 0.001 |
| ESR, mm/h | 19.20 ± 13.44 | 7.8 ± 4.56 | < 0.001 |
| Treatments | |||
| Corticosteroids, (%) | 20/34 (58.82%) | … | |
| Anti-malarials, (%) | 12/31 (38.70%) | … | |
| NSAIDS, (%) | 30/34 (88.20%) | … | |
| Immunosuppressants, (%) | 20/34 (58.82%) | … | |
| Biologics, (%) | … | … | |
Values are means ± DESVEST. ACPAs, Antibodies to citrullinated protein antigens; RF, Rheumatoid factor; CRP, C reactive protein; ESR, Erythrocyte sedimentation rate; NSAIDS, non-steroidal anti-inflammatory drugs; DAS28, Disease activity score 28. Significant differences vs. healthy donors (p < 0.05).